chemieunternehmen.com

Evotec AG today reported financial results and corporate updates for the first half of 2011. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-34-revenue-and-profitable-earnings-growth-revenue-guidance-raised-5018

Evotec AG today announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/p2x7-antagonist-programme-evt-401-to-a-top-tier-global-animal-health-company-partnered-5016

Evotec AG today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/multi-target-collaboration-with-ucb-in-neurodegenerative-and-neurological-diseases-announced-5012

Evotec AG today announced the achievement of specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. and the receipt of a milestone payment.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/milestone-in-an-ion-channel-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-achieved-5010

Evotec AG and Roche today announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs under development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-roche-to-jointly-develop-biomarkers-in-oncology-5008

Evotec AG today announced that it has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/medicinal-chemistry-collaboration-with-active-biotech-5006

Evotec AG and Galapagos NV today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/compound-management-business-from-galapagos-acquired-5004

Evotec AG today announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/milestone-received-as-boehringer-ingelheim-starts-phase-i-clinical-trial-in-pain-5002